首页> 外文期刊>Evidence-based complementary and alternative medicine: eCAM >Systematic Review and Meta-Analysis of Randomized Controlled Trials of Fuke Qianjin Tablet
【24h】

Systematic Review and Meta-Analysis of Randomized Controlled Trials of Fuke Qianjin Tablet

机译:软化对照试验的系统审查与荟萃分析

获取原文
           

摘要

Purpose . The aim of the research was to evaluate the efficacy and safety associated with Fuke Qianjin tablet combined with conventional therapy in the treatment of pelvic inflammatory diseases and associated complications (endometritis) using a meta-analysis approach. Patients and Methods . We searched 8 electronic databases up to December 31, 2019, including PubMed, the Cochrane Library, Embase, Web of Science, CNKI, WanFang, VIP, and SinoMed. Eligible studies were clinical trials of Fuke Qianjin tablet combined with conventional therapy used in the treatment of acute pelvic inflammatory disease, chronic pelvic inflammatory disease, and endometritis. The meta-analysis was performed using STATA15 software. Results . A total of 125 RCTs ( n ?=?14,494) were shortlisted for the meta-analysis, which included 23 trials for acute pelvic inflammatory disease, 69 trials for chronic pelvic inflammatory disease, and 33 trials for endometritis. The overall analysis illustrated Fuke Qianjin tablet combined with conventional therapy was significantly more efficacious than conventional therapy alone across all types of antibiotics treatment for acute pelvic inflammatory disease (OR?=?5.57, 95% CI 4.09–7.58, Z ?=?10.90, ), chronic pelvic inflammatory disease (OR?=?4.70, 95% CI 4.07–5.42, Z ?=?21.21, ) and endometritis (OR?=?5.09, 95% CI 4.03–6.43; Z ?=?13.63, ) in both primary endpoints and secondary endpoints. There is also a trend that Fuke Qianjin tablet combined with conventional therapy has lower adverse reaction rates than conventional therapy alone. Conclusion . Fuke Qianjin tablet combined with conventional therapy showed better clinical efficacy in the treatment of acute pelvic inflammatory disease, chronic pelvic inflammatory disease, and endometritis. There were no obvious drug-related adverse reactions. Fuke Qianjin tablet presented advantages in shortening the remission time of clinical symptoms, reducing the concentration of serum inflammatory factors, improving endometrial thickness, menstruation, and reducing relapse rate.
机译:目的 。该研究的目的是评估与Fuke Qianjin片剂相关的疗效和安全,所述患有常规治疗在治疗盆腔炎性疾病和相关并发症(子宫内膜炎)的常规治疗中使用META分析方法。患者和方法。我们在2019年12月31日搜索了8名电子数据库,包括PubMed,Cochrane图书馆,Embase,Sement,CNKI,WANFANG,VIP和SINOMED。符合条件的研究是Fuke Qianjin片剂的临床试验结合常规治疗用于治疗急性盆腔炎,慢性盆腔炎和子宫内膜炎。使用Stata15软件进行元分析。结果 。对于荟萃分析,总共125个RCT(N?= 14,494),其中包括23例急性盆腔炎炎症疾病试验,慢性盆腔炎的69次试验,以及针对子宫内膜炎的33项试验。整体分析所示的uke Qianjin片剂与常规治疗相结合的常规治疗比单独常规治疗患上所有类型的抗生素治疗(或?5.57,95%CI 4.09-7.58,Z?=?10.90, ),慢性盆腔炎(或?= 4.70,95%CI 4.07-5.42,Z?= 21.21,)和子宫内膜炎(或?= 5.09,95%CI 4.03-6.43; Z?=?13.63,)在两个主要端点和次要端点。还有一种趋势,诸如单独的常规治疗,易通话平板与常规治疗相结合的趋势。结论 。易科Qianjin片剂结合常规治疗表明,在治疗急性盆腔炎,慢性盆腔炎和子宫内膜炎的治疗方面表现出更好的临床疗效。没有明显的药物相关的不良反应。易科Qianjin平板电脑缩短了临床症状的缓解时间,降低了血清炎症因素的浓度,提高子宫内膜厚度,月经和降低复发率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号